SCHEMBL12846643

SCHEMBL12846643

O=Nc1ccccc1CNc1ccc2c(=O)[nH]c3ncccc3c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.52
PARP1 P09874 2/20 0.52
IP6K1 Q92551 1/20 0.37
VCP P55072 1/20 0.36
AURKB Q96GD4 2/20 0.36
IDO1 P14902 1/20 0.36
CCNT1 O60563 2/20 0.36
CDK9 P50750 2/20 0.36
CDC7 O00311 1/20 0.36
DBF4 Q9UBU7 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
NTRK1 P04629 1/20 0.35
NTRK3 Q16288 1/20 0.35
NTRK2 Q16620 1/20 0.35
PARP14 Q460N5 1/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6519121 0.84 AURKA (0.55) AURKAPARP1VCPMAPTALDH1A1
SCHEMBL6525348 0.84 AURKA (0.55) AURKAPARP1IP6K1VCPAURKB
SCHEMBL3454715 0.84 AURKA (0.55) AURKAPARP1AURKBCCNT1CDK9
SCHEMBL3453866 0.84 AURKA (0.55) AURKAPARP1AURKBCCNT1CDK9
SCHEMBL3455169 0.84 AURKA (0.55) AURKAPARP1IP6K1VCPAURKB
SCHEMBL6521905 0.84 AURKA (0.55) AURKAPARP1VCPCDC7MAPT
SCHEMBL6518864 0.81 AURKA (0.51) AURKAPARP1GAAKMT2AL3MBTL1
SCHEMBL6518393 0.81 AURKA (0.51) AURKAPARP1CCNT1CDK9
SCHEMBL3453920 0.81 CDC7 (0.53) AURKAPARP1AURKBCDC7MAPT
SCHEMBL3454371 0.81 AURKA (0.60) AURKAPARP1IP6K1AURKBCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885IP6K1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.